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Although several risk factors such as infarct size have been identiﬁed, the progression/severity of heart
failure (HF) remains difﬁcult to predict in clinical practice. Using an experimental rat model of ischemic
HF and phosphoproteomic technology, we found an increased level of phosphorylated desmin in the left
ventricle (LV) of HF-rats. The purpose of the present work is to assess whether desmin is a circulating or
only a tissue biomarker of HF. We used several antibodies in order to detect desmin, its proteolytic
fragments and its phosphorylated form in LV and plasma by western blot, phosphate afﬁnity electro-
phoresis, mass spectrometry and immunoﬂuorescence. Plasma was treated with combinatorial peptide
ligand library or depleted for albumin and immunoglobulins to increase the sensitivity of detection. We
found a 2-fold increased serine-desmin phosphorylation in the LV of HF-rats, mainly in the insoluble
fraction, suggesting the formation of desmin aggregates. Desmin cleavage products were also detected in
the LV of HF rats, indicating that the increased phosphorylation of desmin results in more susceptibility
to proteolytic activity, likely mediated by calpain activity. The native desmin and its degradation products
were undetectable in the plasma of rat, mouse or human. These data suggest the potential of serine-
phosphorylated form of desmin and its degradation products, but not of desmin itself, as tissue but not
circulating biomarkers of HF.
& 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Chronic heart failure (HF) remains a major cause of illness and
death and its prevalence is increasing with a high rate of morbidity
and mortality [1]. Despite major signiﬁcant advances, HF remains a
therapeutic challenge, and several adverse consequences of HF are
still poorly controlled. New prognostic or diagnostic biomarkers of
HF are still important to ﬁnd and proteomic approaches may be
useful [2].
Novel determinants of post-myocardial infarction (MI)-HF were
already revealed by previous proteomic [3] and phosphoproteomic
[4] approaches. We recently discovered that HF is associated with
decreased levels of myocardial and plasma serine208-phosphory-
lated troponin T (TnT) in an experimental rat model of HF andB.V. This is an open access article u
Professeur Calmette, 59019
inet).conﬁrmed the same decrease in plasma of patients with high LV
remodeling post-MI, suggesting that the level of circulating
phosphorylated TnT could be new biomarker of LV remodeling and
may help to predict the development of HF after MI [5]. More
recently, seven proteins were found differentially expressed in
cardiac tissues in a mouse model of HF (calcineurin transgenic
mice) and their presence in plasma of HF mouse models but also in
HF patients have been investigated [6]. From these candidate
biomarkers highlighted, desmin was found to be detected in
plasma from mouse (45 kDa) and human (22 kDa) species,
suggesting the potential of circulating desmin as biomarker of HF.
Desmin is one of the ﬁve major groups of intermediate ﬁlament
(IFs) that packs myoﬁbrils and mitochondria together inside the
cardiomyocyte and establishes a crucial link with the sarcolemma
and nuclear membranes. Desmin is a 53 kDa protein that forms a
cytoskeletal network across the muscle ﬁber bordering at the
plasma and nuclear membrane and is particularly localized to the
Z-band [7]. Desmin has been described as a major integrator of IFnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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the blood.
Our experimental rat model of ischemic HF offers an easy access to
heart tissue and plasma from the same animal and we have identiﬁed
increased phosphorylation of desmin in LV of HF-rats compared to the
sham-rats (Supplemental Fig.1 and Supplemental Table 1).
It was recently reviewed that during the development of HF,
heart homeostasis should be maintained by the balance between
protein synthesis and degradation [8]. Three major degradation
systems have been identiﬁed, namely the calpain systems, au-
tophagy and the ubiquitin proteasome. Interestingly, desmin is the
target of proteolytic degradation systems and of post-translation
modiﬁcations (PTMs), such as phosphorylation and ubiquitinyla-
tion [9].
Desmin as other cytoskeletal proteins has been hypothesized to
reproducibly degenerate into the same degradation products,
upon the activity of the Ca2þ dependent calpains [10] that have
been localized in heart mitochondria [11]. These recent data sug-
gest that calpains in the heart could be involved in degradation of
desmin that could be secreted into the blood.
The purpose of this work performed in a rat model of HF fol-
lowing MI was to characterize (1) whether cardiac desmin is a
target of the same or other sites of phosphorylation than those
previously described; (2) its susceptibility to degradation proteo-
lytic systems in this experimental model of HF post-MI and, (3) its
potential as being a tissue or circulating biomarker of ischemic HF.2. Materials and methods
2.1. Animal models
All animal experiments were performed according to the Guide
for the Care and Use of Laboratory Animals published by the US
National Institutes of Health (NIH publication NO1-OD-4-2-139,
revised in 2011). Animals were used and experimental protocols
performed under the supervision of a person authorized to per-
form experiments on live animals (F. Pinet: 59-350126, exp. date:
22 June 2016). Approval was granted by the institutional ethics
review board (CEEA Nord Pas-de-Calais N°242011, January 2012).
Before surgery, rats were anaesthetized (sodium methohexital,
50 mg/kg intraperitoneally (IP)), while analgesia was administered
before (xylazine 5 mg/kg IP) and 1 h after surgery (xylazine 50 mg/
kg subcutaneously) as described [12]. Anesthesia and sedation
were controlled by monitoring heart rate. MI was induced in 10-
week-old male Wistar rats (n¼11) (Janvier, Le Genest St isle,
France) by ligation of the left anterior descending coronary artery
[12,13]. Haemodynamic and echocardiographic measurements
were taken 2 months after surgery, followed by heart excision, as
previously described [4,14].
Hearts and blood from 14-week-old C57/BL6 mices (n¼3) were
collected after euthanasia by an overdose of sodium pentobarbital
(50 mg/kg IP).
2.2. Primary cultures of neonate rat cardiomyocytes
Primary cultures of rat neonatal contractile cardiac myocytes
(NCMs) were prepared from heart ventricles of 1- or 2-day-old
rats, killed by decapitation, minced in a balanced salt solution
containing 20 mmol/L HEPES, 120 mmol/L NaCl, 1 mmol/L
NaH2PO4, 5.5 mmol/L glucose, 5.4 mmol/L KCl, and 0.8 mmol/L
MgSO4 [pH 7.4] as previously described [15]. NCMs were seeded at
a density 8105 cells/well in 6-well plates coated with 0.01% of
collagen (Sigma-Aldrich) and cultured in a medium containing
4 parts of DMEM and 1 part of Medium199, 10% horse serum (Life
Technologies), 5% foetal bovine serum (ATCC), 1% penicillin andstreptomycin (10,000 U/mL, Life Technologies) for 7 days at 37 °C
under 5% CO2 atmosphere.
2.3. Plasma preparation
Blood samples from systolic HF-human male patients of is-
chemic origin (LVEFo45%) with NYHA class 2 (INCA, CP 98/94 of
5 November 1998, CHRU Lille-FRANCE) [16], HF-rat and from
control mouse were collected in EDTA-treated tubes and then
centrifuged for 15 min at 1600 g to remove cells and platelets.
After centrifugation, the plasma (resulting supernatant) was col-
lected, aliquoted and stored at –80 °C. Plasmas were treated either
by albumin and IgG (Alb/IgG) depletion or combinatorial peptide
ligand library (CPPL) as previously described [17].
2.4. Tissue fractionation
LV proteins were extracted from 40 mg of frozen tissue (after
removing the infarcted area) with Dounce-Potter homogenization
into ice-cold RIPA buffer (50 mmol/L Tris [pH7.4], 150 mmol/L
NaCl, 1% Igepal CA-630, 50 mmol/L deoxycholate, and 0.1% SDS)
containing anti-proteases (Complete™ EDTA-free, Roche Diag-
nostics), serine/threonine and tyrosine protein phosphatase in-
hibitors (Phosphatase inhibitor Cocktail 2 and 3, Sigma-Aldrich)
and 1 mmol/L Na3VO4, as described previously [4]. H9c2 and NCM
extracts were collected by scraping cells in the same RIPA buffer
described for LV proteins above.
Protein concentrations were determined with a Bradford-based
method protein assay (Biorad, Marnes-la-Coquette, France) and
samples were kept at 80 °C.
2.5. Phosphoproteomic screening
Two-dimensional (2D) gel electrophoresis was performed as
previously described [3]. LV proteins (500 mg) from control (n¼4)
and HF (n¼4) rats at 2 months after surgery were analysed on a
dry 24-cm strip with a pH linear gradient of 3–10 (Immobilin
DryStrip, GE Healthcare). Fluorescent staining of 2-D gel was
performed with Pro-QsDiamond Phosphoprotein Gel Stain (Mo-
lecular Probes™) for 90 min for detecting the phosphorylated
proteins by image acquisation with an Ettan Dige Imager (GE
Healthcare) at an excitation wavelength of 540 nm and an emis-
sion wavelength of 595 nm. Gels were then stained for total pro-
teins with SyprosRuby Protein Gel Stain (Molecular Probes™)
overnight and images of SyprosRuby stained gels were acquired
with the Ettan Dige Imager at an excitation wavelength of 480 nm
and an emission wavelength of 530 nm. Identiﬁcation of spots of
interest (spots 5 and 45) was performed by MALDI-TOF. Detailed
methods have already been described [4].
2.6. Antibodies
Three primary antibodies against desmin were used, clone Y66
(ab32362, Abcam Paris, France), clone DE-U-10 (D1033, Sigma-
Aldrich, Lyon, France) and clone D33 (M0760, Dako, Les Ulis,
France) and one primary antibody against GAPDH (sc-365062,
Santa Cruz) was used to conﬁrm equal total proteins loads. The
secondary antibody, ECL™ anti-mouse and rabbit IgG horseradish
peroxidase-linked whole antibodies from sheep and donkey, re-
spectively (GE Healthcare, Velizy-Villacoublay, France) was used
for western blot. Alexa Fluors 488 coupled anti-mouse and rabbit
secondary antibodies (Invitrogen, Life Technologies) was used for
immunoﬂuorescence studies.
Fig. 1. Phosphoproteomic analysis of LV of HF rats. A: Representative 2D-electophoresis gel of LV proteins from HF (n¼4) and sham-rats (n¼4) stained with ProQDiamonds.
The two polypeptidic spots identiﬁed to be desmin were enlarged and data of modulation of phosphorylated polypeptidic spots (5 and 45) are expressed as mean of
normalized spot's volume7SEM of normalized volume of total spots from sham (white box) and MI (black box)rats at 2 months.*P, 0.05. B: Quantiﬁcation of desmin (soluble
and insoluble fractions) levels in LV (50 mg) of sham- (n¼11) (white box) and HF- (n¼11) (black box) rats at 2 months after MI. Soluble and insoluble desmin were
respectively quantiﬁed in LV proteins extracted in RIPA buffer (50 mg proteins) and Urea/Thiourea buffer (20 mg proteins). C: Ser-phosphorylated, Thr-phosphorylated and
Tyr-phosphorylated desmin were quantiﬁed in LV (50 mg) of sham- (n¼16) (white box) and HF- (n¼19) (black box) rats at 2 months after MI. Data are presented as ratio of
Ser-, Thr- and Tyr-phosphorylated desmin/total soluble desmin. The positions of Mw are indicated on the left. An internal standard was loaded in each gel for the stan-
dardization and quantiﬁcation. Data are expressed as means of an arbitrary unit (AU)7SEM.*P, 0.05.
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2.7.1. Immunoprecipitation
Immunoprecipitation was performed with 50 μg of LV proteins,
2 μL of crude plasma and 75 μg of depleted- and CPLL-treated plasma,
mixed with 2 μL of anti-desmin clone DE-U-10 (Sigma-Aldrich, Lyon,
France) diluted in RIPA buffer. After an overnight incubation at 4 °C on
a rotating device, immune complexes were precipitated at 4 °C for 4 h
on a rotating device with protein A/G magnetic beads (Pierce). Im-
munoprecipitated (IP) complexes were then washed three times with
RIPA buffer before extraction in Laemmli buffer at room temperature
for western blot analysis.
2.7.2. Western blot
Western blot detection of desmin was performed with the three
primary antibodies (1/2000). Brieﬂy, 50 mg of soluble proteins (unless
otherwise stated), 10 mg of insoluble proteins, 1 mL of crude plasma
proteins, 50 mg of of depleted- and CPLL-treated plasma or the whole
IP were resolved on 10% SDS-PAGE (NuPAGE 10% Bis-Tris gel, Life
Technologies) and transferred on 0.2 mm nitrocellulose membranes
(Trans-Blots Turbo™ Transfert Pack, Bio-Rad). Equal total proteins
loads were conﬁrmed by Ponceau red [0.1% Ponceau red, 5% acetic acid
(v/v) (Sigma-Aldrich)] staining of the membranes. The membranes
were then blocked in 5% non-fat dry milk in TBS-Tween buffer for 1 h
before 4 °C overnight incubation with desmin antibodies in blocking
solution. Blots were then washed three times with TBS-Tween 0.1%buffer and incubated with horseradish peroxidase-labelled secondary
antibodies for 1 h (1/10000) in blocking solution. The Chemidocs
camera (Biorad) was used for imaging and densitometry analysis after
membranes were incubated with enhanced chemiluminescence
(ECL™) western blotting detection reagents (Biorad).
2.7.3. PHOS-TAG gels
Fifty μg of soluble LV proteins were separated in 10% Super-
Sep™ Phos-tag™ 50 mM (Wako) at 90 V for 2 h 30 min. After
electrophoretic separation, the excess of metal was removed by
washing the gels twice for 10 min in transfer buffer (NuPAGEs
Transfer Buffer, Invitrogen) containing 10% methanol and
10 mmol/L EDTA. Before proteins transfer onto 0.2 mm PVDF
membrane (Trans-Blots Turbo™ Transfert Pack, Bio-Rad), three
washes of 10 min in transfer buffer containing only 10% methanol
were realized. To detect desmin and its phosphorylated forms,
membranes were blocked 1 h in 5% non-fat dry milk in TBS-Tween
before overnight incubation at 4 °C with desmin clone DE-U-10
antibody (Sigma) at 1/1000 in blocking solution. The following
steps were similar to those described in western blot section.
2.8. Immunoﬂuorescence
Biphotonic confocal microscopy was used for the imaging of 4%
paraformaldehyde and 0.1% Triton ﬁxed/permeabilized NCMs and
frozen rat heart sections (10 mm). Immunoﬂuorescence staining
Fig. 2. A: Structural molecular organization of the rat desmin molecule (P48675) (adapted from [24] and desmin sequence recognized by the three desmin antibodies (clones
Y66 (Abcam, ab32362), DE-U-10 (Sigma-Aldrich, D1033) and D33 (Dako, M0760) used for western blot. A dashed line is shown for the D33 antibody as no information on the
epitope recognized is available. B, C: Western blot analysis of desmin in plasma from rat, mouse and human species with the three desmin antibodies. Plasma was either
depleted for albumin and IgG (B) or treated by combinatorial peptide ligand library (CPLL) (C). M: size marker, C: 50 mg of treated plasma, IP: immunoprecipitated treated
plasma with 2 mL of DE-U-10 desmin antibody, LV: left ventricle (10 mg), S: supernatant of LV IP (10 mg), Ab: antibody (2 mL). The antibody used for the western blot is
indicated on each blot. Arrows indicate the speciﬁc desmin band recognized by the antibodies and ns the non-speciﬁc bands.
M. Bouvet et al. / Biochemistry and Biophysics Reports 6 (2016) 54–62 57was performed by saturation for 30 min with 1% BSA before in-
cubation with the three primary antibodies (dilution 1/100)
against desmin overnight at 4 °C. Alexa Fluors 555 coupled anti-
mouse and rabbit secondary antibodies at dilution 1/500 was in-
cubated for 30 min at room temperature with mounting medium
(H-1500, Vectashield, Vector). Staining was visualized with the
40 and63 objectives of LSM710 confocal microscope followed
by Zen image acquisition and software analysis (Zeiss). Images
were acquired with a resolution of at least 10241024.
2.9. Mass spectrometry analysis
2.9.1. 1D SDS-PAGE and digestion of proteins
Forty mg of proteins were denatured with Laemmli sample
buffer (v/v), loaded onto 1D SDS-PAGE (12%) using 2 mm-stacking
gel, and run for 10 min in order to concentrate the proteins before
staining with colloidal coomassie G-250 (Bio-Rad). A slice per
sample was excised, cut in small pieces (1 mm3) and washed twice
with 120 ml of 25 mmol/L ammonium bicarbonate (NH5CO3)/
acetonitrile (ACN), before dehydration with 100 ml ACN for 5 min.
Prior to digestion, the gel bands were reduced with 10 mmol/L
DTT, alkylated with 50 mmol/L iodoacetamide (IAA) and digested
with 0.4 mg of sequencing grade porcine trypsin (Promega, Madi-
son, WI) for 16 h. The peptides were extracted with 25 mmol/L of
NH5CO3/ACN (v/v) in 0.1% formic acid (FA), dried with vacuum
concentration centrifuge (Uniequip GmbH, Munich, Germany) and
resuspended in 12 ml of 0.1% FA.2.9.2. Liquid chromatography and mass spectrometry analyses
Nano-LC analyses were performed on an Ultimates 3000
RSLCnano System (Dionex/Thermo Scientiﬁc). Each sample (3 ml)
was loaded into a trap column (Acclaim PepMap, 5 mm300 mm
inner diameter, C18, 5 mm, 100 Å), Dionex, Sunnyvale, CA) at 5 ml/
min in 0.1% FA and 2% ACN for 5 min. The peptides were then
concentrated on an analytical column (Acclaim PepMap RSLC,
15 cm75 mm inner diameter, C18, 2 mm, 100 Å, Dionex) by a sol-
vent A (0.1% FA in HPLC grade water) and a solvent B (0.1% FA in
HPLC grade ACN) at a ﬂow rate of 300 nl/min. Peptides were then
eluted using a C18 analytical column and a 240% linear gradient
of solvent B for 46 min followed by a washing step (6 min of 80%
solvent B) at a ﬂow rate of 300 nl/m.
2.9.3. Mass spectrometry analyses and protein identiﬁcation
Eluted peptides from the C18 analytical column were analysed
by a Q-Exactive mass spectrometer (Thermo Scientiﬁc, Bremen,
Germany) with a spray voltage et up at 1.9 kV, and capillary
temperature set up at 275 °C. Data acquisition was performed in a
data-independent mode consisting of a full scan MS over the range
m/z 230–2000 with resolution of 70,000 at m/z 200 and a full scan
MS/MS of the ten most intense peaks. MS/MS data were acquired
using a 2 m/z units ion isolation window and a collision energy of
24. These experiments performed in triplicate for each sample
were fully controlled by Thermo Xcalibur 3.0 (Thermo Fisher
Scientiﬁc).
All data ﬁles (*.raw) collected during nanoLC-MS/MS analyses
Fig. 3. Mass spectrometry analysis of rat, mouse and human plasma (A) and rat LV (B) samples. A: Venn diagram of identiﬁed proteins in crude plasma (upper panel) and
plasma immunoprecipitated with DE-U-10 desmin antibody (lower panel). For plasma, 4 samples from 2 HF- (HF1, HF2) and 2 sham- (C1, C2) rats, 3 different samples from
mouse (M1, M2, M3) and human (H1, H2, H3) were analysed. B: Quantiﬁcation of desmin in LV samples corresponding to the rats tested for plasma (HF1, HF2, C1, and C2).
Levels of the 3 replicates injection of each sample show the reproducibility (left panel). Average levels of desmin in LV rats with standard deviation less than 10% (middle
panel). Ratio levels of desmin in LV rats with the sham-C1 rats considered as the lower level for the ratio calculation (right panel). Detailed information's are presented in
Table 1.
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1.4 (Thermo Fisher Scientiﬁc). The MS/MS spectra were ﬁltered
with 1.5 signal-to-noises (S/N) threshold. Tryptic monoisotopic
peptide masses were searched for in the National Center of Bio-
technology Information (Homo sapiens protein sequences (118,210
entries), Rattus norvegicus protein sequences (84,085 entries) and
Mus musculus protein sequences (174,503 entries)) using Mascot
(Version 2.4.1, Matrix Science, London, UK) and Sequest HT
(Thermo Fisher Scientiﬁc) with a mass tolerance of 10 ppm for
precursor ions and 0.02 Da for fragment ions and 3 missed clea-
vages per tryptic peptide. Chemical modiﬁcations such as carba-
midomethylation (cysteine), acetylation of N-terminal protein,
oxidation (methionine) and deamidation (glutamine, asparagine)
were taken into consideration. The criteria to accept identiﬁcation
included a score of probability greater than 25 for Mascot and
greater than 2 for Sequest HT XCorr. The target-decoy database
search allowed us to verify and estimate the false positive iden-
tiﬁcation rate of our study below 1% [18].
2.9.4. Label-free quantiﬁcation of desmin
Desmin abundance was quantiﬁed by calculating the area
under the curve for each precursor ion identiﬁed as a peptide
mapping to desmin at 2 ppm with Proteome Discoverer. The
average level was calculated as the mean value of the area ob-
tained for each identiﬁed peptide in the three replicates. Theratios of desmin were normalized with the sample containing
the lowest amount of desmin.
2.10. Statistical analysis
Data are expressed as means7SEM. Statistical analysis of the
cardiac functional parameters was performed by the Wilcoxon
test. For the other analyses, an unpaired t-test was used to eval-
uate differences between groups. A value of Po0.05 was con-
sidered statistically signiﬁcant.3. 3. Results
3.1. Levels of desmin and its phosphorylated forms in left ventricle of
rats with heart failure
By phosphoproteomic screening performed in LV of HF-rats
compared to sham-rats, we previously detected 69 polypeptidic
spots and identiﬁed 30 different proteins with modulation of their
phosphorylation level (Supplemental Fig. 1 and [4]). We focused
on two spots labelled 5 and 45 presented on enlarged 2D (Fig. 1A)
that showed an increase (by a mean factor of 4) in phosphorylation
in the LV of sham-rats compared to the HF rats (spot 5:0 vs
3.2672.27 and spot 45:0.8970.52 vs 1.1970.72 A.U.). The two
Table 1
Summary of desmin identiﬁcation in the 4 different rat LV samples (HF1, HF2, C1
and C2).
Sample HF1 HF2 C1 C2
∑ coverage Left ventricle 91% 91% 91% 92%
LV IP 91% 97% 94% 94%
Plasma – – – –
Pl IP – – – –
∑ unique
peptides
Left ventricle 56 58 54 60
LV IP 69 78 75 78
Plasma – – – –
Pl IP – – – –
∑ peptides Left ventricle 62 64 58 68
LV IP 75 84 82 83
Plasma – – – –
Pl IP – – – –
Mascot/Sequest
PSMs
Left ventricle 1867/
2628
1476/
2102
1384/
2239
1853/
2805
LV IP 2621/
2967
2542/
3248
2912/
3706
3283/
4918
Plasma – – – –
Pl IP – – – –
LV IP: left ventricle immunoprecipitated with desmin antibody, PL IP, plasma im-
munoprecipitated with desmin antibody, HF: heart failure, C: control, ∑ coverage:
total percentage of the protein sequence covered by identiﬁed peptides (combined
Mascot and Sequest analyses), ∑ unique peptides: Total number of peptide se-
quences unique to a protein (combined Mascot and Sequest analyses), ∑ peptides:
Total number of distinct peptide sequences identiﬁed in the protein (combined
Mascot and Sequest analyses), PSMs: Total number of identiﬁed peptide sequences
(peptide spectrum matches),-: no identiﬁcation of desmin.
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As previously shown, no detection of modulation of desmin
levels in LV of HF rats was observed during the previous proteomic
screening [3]. These previous data were conﬁrmed here by wes-
tern blot using an antibody speciﬁc to desmin in both soluble
(RIPA extracts) and insoluble (thiourea/urea extracts) (Fig. 1B).
We then looked for the amino acids (Ser, Thr and Tyr) involved
in the increased phosphorylation of desmin and observed that
desmin was phosphorylated on Serine (Ser), Threonine (Thr) and
Tyrosine (Tyr) but only the phosphorylation of desmin on Ser was
modulated in the LV of HF- compared to the sham-rats (Fig. 1C).
We veriﬁed the speciﬁcity of the Ser-phosphorylation by treat-
ment of the LV proteins with alkaline phosphatase, leading to the
complete cleavage of phosphorylation and consequently to an
absence of signal (not shown).
3.2. Levels of desmin in plasma
To verify for the presence of desmin in plasma, we used dif-
ferent antibodies from 3 different clones that recognized both
human, rat and mouse species (Fig. 2A). The desmin antibodies
(clone Y66, raised in rabbit and used in Fig. 1 and clone DE-U-10,
raised in mouse) recognized the C-terminal part of the sequence
corresponding respectively to the desmin tail (412–469 AA) and
the Col2B region (325–372 AA). The third one (clone D33, raised in
mouse) was previously used for detecting desmin in heart and
plasma from mouse and human species [6].
First, we analysed crude plasma from rats and humans for the
presence of desmin and did not ﬁnd any speciﬁc bands (data not
shown). We then treated plasma from rat, mouse and human
species either for CPPL or Alb/IgG depletion in order to access low-
abundance proteins that we analysed directly or after im-
munoprecipitation (IP) with the desmin antibody (clone DE-U-10)
to increase the sensitivity of detection. We observed different
western blots either at short (Fig. 2B–C) and long exposure (Sup-
plemental Fig. 2) performed with the three different antibodies.
The Y66 antibody, produced in rabbit, which recognizes theC-terminal part of desmin, has the best speciﬁcity as shown by the
speciﬁc band detected in crude and IP LV proteins at 53 kDa (ar-
row) and no band detected in supernatant of IP at short exposure
or with the antibody loaded, which was used for the im-
munoprecipitation of desmin. But, we were unable to detect spe-
ciﬁcally desmin in the plasma of any species either after CPPL or
Alb/IgG depletion with this antibody. The DE-U-10 desmin anti-
body recognized only desmin in LV proteins. The bands detected in
plasma were all unspeciﬁc (Supplemental Fig. 2). Surprisingly, the
D33 antibody which was raised against the same full length des-
min sequence as the DE-U-10 antibody was less sensitive and less
speciﬁc with the highest background detected at short exposure
(Fig. 2B–C) and detection of desmin only in crude LV at long ex-
posure (Supplemental Fig. 2). We have also veriﬁed the speciﬁcity
of IP without antibody, showing that desmin was detected in the
supernatant IP (corresponding to the unbound proteins) and not in
the IP (bound proteins) by western blot with the DE-U-10 desmin
antibody (Supplemental Fig. 3).
To ensure the absence of desmin in plasma, we also perform
mass spectrometry analysis of crude and plasma im-
munoprecipitated with the DE-U-10 desmin antibody (Fig. 3A)
from rat, mouse and human species. We used LV proteins as po-
sitive control to ensure recovery of the eluted desmin peptides
(Fig. 3B). In any of crude or IP plasma samples (rat (n¼4), mouse
(n¼3) and human (n¼3) samples), no desmin peptides were de-
tected despite a high number of peptides identiﬁed (322 in rat,
309 in mouse and 259 in human samples) (Fig. 3A). Conversely,
the same MS approach used with LV proteins has identiﬁed des-
min successively and reproducibly with sequence coverage of
more than 90% (Fig. 3B, Table 1). Interestingly, by this approach we
have identiﬁed the aminoacids phosphorylated in LV of the rat
model of ischemic HF to be the serine 25, 28, 31, 32, 60, 68, 81, 91,
329, 343 and 431 (Supplemental Fig. 4).
3.3. Biochemical characterization of desmin
To understand why desmin is not detected in plasma, sug-
gesting that desmin is not secreted from cardiomyocytes into the
blood, we characterized the level of desmin upon cell fractiona-
tion. Desmin level was analysed in soluble (RIPA buffer) and in-
soluble (urea/thiourea buffer) fraction extracted from LV of sham-
and HF-rats. At short exposure, we observed that most of desmin
was detected in the insoluble fraction of LV proteins and inter-
estingly a lower molecular weight band was detected in HF rat
(Fig. 4A), as already shown with the DE-U-10 antibody (Fig. 2B–C).
Interestingly, the same proﬁle was observed with two desmin
antibodies (DE-U-10, upper panel and Y66, lower panel in Fig. 4A).
To determine if there is any difference in non-phosphorylated/
phosphorylated desmin patterns depending on the soluble/in-
soluble fraction, we used the phosphate afﬁnity SDS-PAGE (Phos-
tag™), which has the properties to delay phosphoproteins during
electrophoresis, thus allowing the separation of the phosphory-
lated (mono-, bis-, or more) forms from their unphosphorylated
form according to their number of phosphate moieties. We did not
observe any signiﬁcant differences in unphosphorylated or phos-
phorylated forms of desmin either in soluble fraction or insoluble
fraction of LV proteins independently of the amount of desmin
detected which is rather low in soluble fraction compared to in-
soluble fraction (Fig. 4B).
Finally, we characterize the subcellular localization of desmin
by immunoﬂuorescence in NCMs and rat LV (Fig. 5). Interestingly,
the desmin stainings in NCMs (Fig. 5A–C) and LV (Fig. 5D–F) were
different depending on the desmin antibodies. The Y66 and DE-U-
10 antibodies detected desmin in intermediate ﬁlaments both in
NCMs (Fig. 5A–B) and LV (Fig. 5D–E). The D33 antibody gave a
completely different staining for desmin in NCMs (Fig. 5C) and
Fig. 4. Biochemical characterization of desmin. A:Western blot analysis of desmin in LV proteins (50 mg) extracted from sham- and HF-rats in RIPA and Urea/Thiourea buffer.
The ponceau red staining gel (left panel) and the western blot images (right panel) with desmin DE-U-10 (upper panel) and Y66 (lower panel) antibodies at short exposure
are presented. B: Western blot analysis of desmin in LV proteins separated using Phos-Tag (8%, 50 mmol/L) afﬁnity electrophoresis performed with the DE-U-10 antibody. LV
proteins are extracted in RIPA (50 mg of proteins) (upper panel) or Urea/Thiourea (20 mg of proteins) (lower panel) buffer. The western blot images presented are at long
exposure (41000 s) for RIPA extraction and short exposure (12 s) for Urea/Thiourea extraction. Arrows indicate the speciﬁc desmin bands recognized. M: size marker.
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These data strengthened the different patterns obtained by wes-
tern blots performed with the different desmin antibodies (Fig. 2).4. Discussion
In the present study, we found a 2-fold increased phosphorylation
of desmin levels by phosphoproteomic analysis in a well character-
ized rat ischemic HF experimental model in which the induction of
anterior MI leads to LV remodeling and to HF [14]. We aimed to in-
vestigate 1) the behavior of phosphorylated desmin because post-
translational modiﬁcations of desmin has been shown to cause dis-
turbance of intermediate skeletal network [19] and, 2) the potential
of phosphorylated desmin as biomarker of events linked to ischemic
HF as desmin was recently shown to be present in plasma [6].
As shown previously [3], we did not ﬁnd any modulation of
total desmin either in soluble or insoluble fractions of LV proteins
in our model of impaired systolic heart function. Various behavior
of desmin has been shown depending upon the experimental
animal models of HF used. Our data are in accordance with those
recently published in a canine pacing model of desynchronous HF,
characterized by pressure overload, showing increased levels of
phosphorylated desmin [20]. Interestingly, it was recently shown
in two different mice models, one of diastolic dysfunction obtained
by transverse aortic constriction [21] and the other one, thetransgenic calcineurin model, characterized by a phenotype of end
stage heart failure [6], an up-regulation of desmin with no pro-
portional increase in phosphorylation.
We also identiﬁed that most of the phosphorylated desmin was
present in the insoluble fraction of LV, suggesting the formation of
desmin aggregates in failing heart, as described in desminopathies
in which desmin causative mutations led to the accumulation of
insoluble desmin-containing aggregates, and destructive changes
in the sarcomere [22]. By mass spectrometry, we have identiﬁed
new serines to be phosphorylated and conﬁrmed the Ser 28 and
32 (rat species) already described in different experimental mod-
els [20,23].
Pathological hyperphosphorylation of IF is frequently accom-
panied by IFs reorganization and aggregation [19]. Desmin is
considered as a major integrator of contractile apparatus to the
nucleus and other organelles and is a critical factor for maintaining
IFs structure. Its increased phosphorylation might lead to the
network destabilization and formation of aggregates toxic for the
cardiomyocyte [7]. Our phosphoproteomic data have also shown
two 2D spots with different Mw and pI identiﬁed as being desmin
in accordance with the multiple desmin species detected in a
model of hypertrophied cardiomyocytes [24]. These multiple
desmin species has been suggested to be products of cleavage by a
Ca2þ-activated proteinase [25], which was characterized later as
being calpain [26]. Interestingly, calpains play a critical role in
heart protein homeostasis and are activated during HF
Fig. 5. Representative immunoﬂuorescence stainings of desmin (green) in primary culture of neonate rat cardiomyocytes (NCM) (A, B, C) and in left ventricle from control rat
(D, E, F) with the three desmin antibodies. Nuclei are stained in blue (DAPI).
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might be a proteolytic cleavage of desmin by calpain (TRAP in
position 76–80 which is a pig desmin fragment obtained after
incubation by calpains and analysed by N-terminal sequencing
[26]. These cleavages are located in the head domain of the desmin
whose aminoacid sequence is conserved in rat, mouse, pig and
human species (supplemental Fig. 4). This is in accordance with
previous description of 2 isoforms of desmin in endomyocardial
biopsies from familial HF patients [27].
We may speculate that the increased phosphorylation of des-
min induced increased desmin cleavage by calpain in order to
protect cardiomyocytes from the aggregates. Calpain is required
for localized cytoskeleton remodeling at injury sites and plasma
membrane maintenance under hemodynamic stress [8]. This ac-
tivation of calpains at injured sites leads to proteolysis of desmin
for clearance and membrane repair (patch vesicle). Desmin de-
gradation products upon damage and processing by calpain might
be at the origin of desmin in plasma. We could not exclude that the
presence of phosphorylation sites may impact the susceptibility of
desmin to cleavage. It was shown with a missense mutation in
desmin tail domain, the existence of interplay between the head
and tail domain that may affect the susceptibility of desmin to
speciﬁc proteases and abolish its Z-disc localization [28]. But
contrarily to a previous publication [6], we were unable to detect
desmin in plasma of mouse, rat and human despite the use of
several desmin antibodies and a sensitive mass spectrometry
analyses.5. Conclusions
From our data and others, we speculate that the increased
phosphorylated form of desmin detected in ischemic HF increased
susceptibility of desmin to proteolysis, resulting in desmin de-
gradation products through calpain-mediated cleavage. The next
step requires using calpain inhibitors or cells deﬁcient in calpain in
order to explore and identify precisely the speciﬁcity and the sites
of desmin cleavages. Contrarily to others [6], we were unable to
detect speciﬁcally desmin in plasma from different species. We
should not exclude that in late/aggravated stages of HF of non-
ischemic origin, such as the model of 14 weeks-old calcineurin
transgenic mice, cleaved forms of desmin can be released passively
from the heart due to disruption of architecture. In a TNF-induced
mice model of cardiomyopathy, desmin was shown to be cleaved
by caspase 6 revealing 24 and 29 kDa fragments in heart, which
may be responsible for a loss of intercalated disk localization [29].
Interestingly, it was shown that the desmin expression and pattern
of striation by immunostaining correlated with the level of myo-
cardial injury in patients with idiopathic dilated cardiomyopathy
and may be used a marker of HF progression [30].
Deciphering the functional serine(s) involved in the hyper-
phosphorylation of desmin during the cardiac remodeling process
following MI will be important with the purpose of developing
speciﬁc tools, such as antibodies against the serine-phosphory-
lated desmin in order to detect phosphorylated-desmin degrada-
tion products and study the behavior of desmin, such as its loca-
lization to Z-disc or aggregate formation. Future studies will need
to characterize the utility of post-translational modiﬁcations as
M. Bouvet et al. / Biochemistry and Biophysics Reports 6 (2016) 54–6262circulating or tissue biomarkers and the targets involving IFs
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